"[DelSite's] polymer is capable of gelling in-situ in contact with body fluids, including the oral fluid, and is mucoadhesive, which together provide the formulation prolonged residence time and a sustained antigen release. In addition, the polymer has an antigen stabilization effect. The formulation can be prepared in various forms - a liquid, a soft gel, a powder, or a dried pad."
The terms of agreement include the following: - (in the next twelve months) Carrington will formulate vaccine antigens supplied by IVI for sublingual delivery and IVI will conduct animal testing.
- The target vaccine antigens and formulation forms will be selected by mutual agreement.
- DelSite has agreed to not enter into another agreement to use GelSite® (its polymer delivery technology for sublingual vaccines) without the consent of IVI.
- Arrangements for commercial development and marketing of vaccines candidates generated by the collaboration would be decided upon by Carrington and IVI as equal joint owners of the prospective products.
The IVI is the world's only international organization devoted exclusively to developing and introducing new-generation vaccines for developing countries.
Find more details from the press release.
Comment Preview